Polypeptides, nucleic acids and uses thereof
US-9309314-B2 · Apr 12, 2016 · US
Polypeptides, nucleic acids and uses thereof
US9902761B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9902761-B2 |
| Application number | US-201415101304-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 3, 2014 |
| Priority date | Dec 3, 2013 |
| Publication date | Feb 27, 2018 |
| Grant date | Feb 27, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating hypertension in a subject in need thereof, the method comprising administering a therapeutically effective amount of the ELABELA polypeptide selected from the group consisting of polypeptides of SEQ ID NOs 2-18.
Assignees
Inventors
Classifications
for HIV · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antihypertensives · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9902761B2 cover?
- We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripoten…
- Who is the assignee on this patent?
- Agency Science Tech & Res, Agency For Science Tech And Research A*Star
- What technology area does this patent fall under?
- Primary CPC classification C07K14/575. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).